
In Vitro and in Vivo Efficacy of Liposomal Ciprofloxacin Formulations Against Mycobacterium Avium and Mycobacterium AbscessusAward last edited on: 11/16/2017
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$972,650Award Phase
2Solicitation Topic Code
NIAIDPrincipal Investigator
James D BlanchardCompany Information
Phase I
Contract Number: N/AStart Date: 00/00/00 Completed: 00/00/00
Phase I year
2017Phase I Amount
$1Phase II
Contract Number: 1R44AI134572-01Start Date: 00/00/00 Completed: 00/00/00
Phase II year
2017(last award dollars: 2018)
Phase II Amount
$972,649Public Health Relevance Statement:
Project Narrative Lung infections by Mycobacterium avium and Mycobacterium abscessus are increasing in incidence (3). M. avium-Mycobacterium intracellulare has become a common complication in patients with chronic lung disease, e.g., emphysema, cystic fibrosis (CF) or bronchiectasis (4,5). Mycobacterium abscessus is associated with infection in patients with CF or follows M. avium infection in patients with chronic pulmonary conditions. Unfortunately, therapies for these infections often fail or are not tolerated, and the infections further compromise these patients' health. Also, a large percentage of the patients develop infections that are resistant to the available antibiotics, presumably because of inadequate concentrations at the sites of infection. There is thus a need to develop new anti-mycobacterial therapies for both diseases. The objective of this project is to test the efficacy of three new liposomal formulations of ciprofloxacin, developed specifically for inhalation, to overcome the problems of systemic therapy in combination with other antimycobacterial agents, using in vitro and in vivo models of M. avium and M. abscessus lung infection.
Project Terms:
Adverse effects; aerosolized; AIDS/HIV problem; Amikacin; Animals; Antibiotic Resistance; Antibiotics; Antimycobacterial Agents; Bacteria; base; Benchmarking; Biological Assay; Breathing; Bronchiectasis; Chronic; Chronic lung disease; Ciprofloxacin; Clarithromycin; Clinical; clinical efficacy; Clinical Research; Clinical Trials; Colony-forming units; Combined Antibiotics; Combined Modality Therapy; commercial application; Complex; Complication; Cyclic GMP; Cystic Fibrosis; cystic fibrosis patients; Data; design; Disease; Dose; efficacy testing; efficacy trial; Encapsulated; Ethambutol; experimental study; FDA approved; Formulation; Funding; Future; Genus Mycobacterium; Health; Human; Imipenem; improved; In Vitro; in vivo; in vivo Model; Incidence; Infection; Ingestion; intraperitoneal; Killings; Linezolid; Liposomes; liquid formulation; Lung; macrophage; Microbial Biofilms; Modeling; mouse model; Mus; mycobacterial; Mycobacterium avium; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections; Mycobacterium intracellulare; nanocrystal; Nebulizer; non-tuberculosis mycobacteria; novel; Oral; Organism; Patients; Pharmaceutical Preparations; Phase; phase 1 study; Predisposition; Preparation; Program Development; Pseudomonas aeruginosa; Pulmonary Emphysema; Research; Research Infrastructure; Resistance; resistant strain; Safety; Saline; Site; System; Systemic Therapy; Testing; Time